Aurobindo up 1%; gets third USFDA nod in 2 days, BoAML positive

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Moneycontrol BureauShares of Aurobindo Pharma gained 1 percent intraday Wednesday on the back of US Food & Drug Administration (USFDA) final approval to manufacture and market Isosulfan Blue Injection single-dose vials.The product is expected to be launched in Q4 FY15-16. This is third approval received by the company in the last two days. Yesterday, the company had received two approvals from USFDA to manufacture and market Celecoxib Capsules and Levetiracetam Injection USP.The approved ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Lymphazurin TM Injection, 1 percent, of Covidien. The approved product has an estimated market size of USD 57 million for the twelve months ending December 2015 according to IMS.Bank of America Merrill Lynch (BoAML) has reiterated its buy rating with target of Rs 1050. The broking firm see multiple growth levers for the stock and estimate its core earnings CAGR at 26 percent over FY16-18E."We are 11 percent/9 percent ahead of consensus for FY17/18, and would expect the street to upgrade estimates after 3Q/4Q FY16 results, as per report.At 11:05 hrs Aurobindo Pharma was quoting at Rs 770.10, up Rs 3.55, or 0.46 percent on the BSE.Posted by Rakesh Patil